Morning Overview on MSN
A massive long-term review just tied GLP-1 weight-loss drugs to sharply lower rates of heart attacks, strokes, heart failure, and early death
When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what ...
GLP-1 drugs tirzepatide and semaglutide may offer increased protection against heart attack, stroke and death from any cause, according to a November study published in Nature Medicine and presented ...
The Canadian Press on MSN
Generic semaglutide to hit Canadian pharmacies this week at a fraction of the cost of Ozempic
TORONTO — Two generic versions of Ozempic are set to start arriving in Canadian pharmacies this week, which means patients who use the drug to treat diabetes or for weight loss may have more options ...
Tirzepatide and semaglutide are popular weight loss drugs. Learn how they differ in effectiveness, cost, and side effects.
In a phase III trial, orforglipron yielded better HbA1c reduction compared with oral semaglutide at 52 weeks. Gastrointestinal side effects were more common with orforglipron, leading to more ...
Scripps case series suggests some patients can maintain GLP-1 weight loss by spacing semaglutide or tirzepatide doses.
A study has found that treatment with Wegovy (semaglutide) led to reduced triptan usage in women. However, no significant ...
Some Canadian pharmacists are already stocking their shelves with generic versions of semaglutide, more commonly known by the ...
Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to ...
The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results